Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice‐weekly carfilzomib (45 and 56 mg/m(2)) in combination with lenalidomide and dexamethasone

Detalles Bibliográficos
Autores principales: Korde, Neha, Mastey, Donna, Tavitian, Elizabet, Mailankody, Sham, Lesokhin, Alexander, Hassoun, Hani, Smith, Eric L., Lendvai, Nikoletta, Hultcrantz, Malin, Shah, Urvi, Tan, Carlyn, Lu, Sydney, Diamond, Benjamin, Salcedo, Meghan, Werner, Kelly, Chung, David J., Scordo, Michael, Shah, Gunjan L., Lahoud, Oscar, Landau, Heather, Arcila, Maria, Ho, Caleb, Roshal, Mikhail, Dogan, Ahmet, Derkach, Andriy, Devlin, Sean M., Giralt, Sergio A., Landgren, Ola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Correspondences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251553/
https://www.ncbi.nlm.nih.gov/pubmed/33661527
http://dx.doi.org/10.1002/ajh.26150

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8251553/
https://www.ncbi.nlm.nih.gov/pubmed/33661527
http://dx.doi.org/10.1002/ajh.26150

Ejemplares similares